Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 5/20 | 0.56 |
| ▸ | GPR88 | Q9GZN0 | 4/20 | 0.54 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.49 |
| ▸ | AKT1 | P31749 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | NEK4 | P51957 | 2/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.49 |
| ▸ | PRKG2 | Q13237 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.49 |
| ▸ | PRKCG | P05129 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28262023 | 0.87 | CTRB1 (0.56) | CTRB1GPR88METAP2METAP1 | |
| SCHEMBL12311000 | 0.87 | CTRB1 (0.56) | CTRB1GPR88METAP2METAP1 | |
| Hydrochloric Acid SCHEMBL18989594 | 0.84 | CTRB1 (0.54) | CTRB1GPR88METAP2METAP1SOAT1 | |
| Hydrochloric Acid SCHEMBL18989447 | 0.84 | CTRB1 (0.54) | CTRB1GPR88METAP2METAP1SOAT1 | |
| Hydrochloric Acid SCHEMBL18989448 | 0.84 | CTRB1 (0.54) | CTRB1GPR88METAP2METAP1SOAT1 | |
| SCHEMBL5967240 | 0.83 | CTRB1 (0.52) | CTRB1GPR88 | |
| SCHEMBL7433148 | 0.81 | RPS6KA5 (0.52) | GPR88RPS6KA5AKT1GSK3BNEK4 | |
| SCHEMBL5672684 | 0.81 | RPS6KA5 (0.52) | GPR88RPS6KA5AKT1GSK3BNEK4 | |
| SCHEMBL4598191 | 0.80 | ROCK1 (0.55) | GPR88RPS6KA5AKT1GSK3BNEK4 | |
| SCHEMBL115980 | 0.80 | ROCK1 (0.55) | GPR88RPS6KA5AKT1GSK3BNEK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268273-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON PHARMACEUTICALS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2510925-B1 | Small-Molecule modulators of TRP-P8 activity | DENDREON CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| US-8618155-B2 | Small-molecule modulators of Trp-p8 activity | DENDREON CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-8614243-B2 | Small-molecule modulators of Trp-p8 activity | DENDREON CORPORATION (US) | 2013-12-24 | — | — | US | disclosed |
| EP-1986622-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORP (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2510925-A2 | Small-Molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120225871-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2012-09-06 | — | — | US | disclosed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7741355-B2 | Small-molecule modulators of TRP-p8 activity | DENDREON CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | TRPC4, TRPC3, TRPC1 | CTRB1 2748/4885GPR88 33/4885RPS6KA5 2313/4885 |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | CTRB1 2748/4885GPR88 33/4885RPS6KA5 2313/4885 |
| US-20120225871-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | CTRB1 2748/4885GPR88 33/4885RPS6KA5 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.